X

Stay Connected

Sign Up for Updates

network1.png

PPA strives to improve patient health, advance medical innovation and fuel economic growth.

LEARN MORE
network1.png

The PhRMA Foundation supports the research and career endeavors of scientists in drug discovery and development.

LEARN MORE
network1.png

Access Better Coverage educates consumers about the ABCs of health coverage and access to medicines.

LEARN MORE
network1.png

We Work For Health aims to increase awareness by uniting workers throughout the industry.

LEARN MORE
network1.png

Patent protection should always be considered by an inventor during the initial stages of their invention.

LEARN MORE
logo_white_MyOldMeds-New-1.png

Working to spread awareness and education about the importance of secure drug disposal.

LEARN MORE
LTAC_NEW21.png

Many Americans are struggling to afford their medicines and have important questions about their medicine costs. Let's Talk About Cost addresses these questions.

LEARN MORE
logo_white_LTAM.png

There are a lot of conversations in Washington about how to change Medicare Part D, but they aren't always focused on what seniors care about most: affordability and predictability.

LEARN MORE
 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Mark Grayson

Mark Grayson Mark Grayson is a former deputy vice president of public affairs at PhRMA focusing on intellectual property, trade and international issues.

Recent Posts

Poll respondents appreciate economic benefits of innovation and call for more protections

By Mark Grayson  |    July 11, 2017
Increasingly, economists and international organizations are recognizing innovation as one of the most important drivers of economic and social progress and stability. In fact, a report released...   Read More

As U.S. looks to modernize NAFTA, strong enforcement of existing obligations should be a top priority

By Mark Grayson  |    June 13, 2017
Yesterday, PhRMA filed comments on negotiating objectives for the modernization of the North American Free Trade Agreement (NAFTA). The Administration’s review of our trading relationship with Mexico...   Read More

ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation

By Mark Grayson  |    May 5, 2017
America’s biopharmaceutical leadership is a result of a robust medical innovation ecosystem driven by several factors: a free-market economy that rewards innovation, strong intellectual property...   Read More

NAFTA tribunal fails to rule on Canada’s patent utility doctrine

By Mark Grayson  |    April 4, 2017
While Canada may have prevailed in the recent North American Free Trade Agreement (NAFTA) tribunal case against Eli Lilly, the promise utility doctrine continues to harm their economy. And,...   Read More

How innovative medicines are benefiting countries across the globe

By Mark Grayson  |    March 1, 2017
It is important to look at costs across health care systems to fully understand how life-changing medicines are providing a more sustainable path forward. Across the globe, medicines are allowing...   Read More

PhRMA urges USTR to protect American innovators abroad

By Mark Grayson  |    February 10, 2017
Yesterday, PhRMA submitted comments for the 2017 Special 301 Report the Office of the U.S. Trade Representative (USTR) will publish in April. The comments highlight serious intellectual property and...   Read More

New report provides recommendations for securing and protecting IP

By Mark Grayson  |    December 13, 2016
This week, the White House Office of the U.S. Intellectual Property Enforcement Coordinator (IPEC) issued a Joint Strategic Plan outlining actions government, industry, educational institutions and...   Read More

New report highlights need to speed patent examination

By Mark Grayson  |    November 2, 2016
The Center for the Protection of Intellectual Property released a new report, “The Long Wait for Innovation: The Global Patent Pendency Problem,” documenting the growing global challenge of patent...   Read More

Study highlights negative impact of Canada's promise doctrine on R and D investment

By Mark Grayson  |    October 21, 2016
A newly published study from Charles River Associates (CRA) has found that Canada’s approach to intellectual property (IP), innovation and patient care is being jeopardized because of its adoption...   Read More

New report highlights impact of intellectual property on U.S. economy

By Mark Grayson  |    October 13, 2016
In late September, the U.S. Department of Commerce released a comprehensive report that found intellectual property (IP) intensive industries contribute more than $6 trillion (38.2 percent) to U.S....   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates

Trending Posts

Most Popular Posts

Pharmaceutical Research and Manufacturers of America®
950 F Street, NW Suite 300, Washington, DC 20004

Please be advised that this page contains pixel tags. To learn more about what pixel tags are, why and how
we and third parties use pixel tags, and how that use affects you, visit our privacy policy and review
"1. Information Collection."